# Phase IIA Study in Patients With Schizophrenia

> **NCT00686998** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 106 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** AZD2624
- **DRUG:** Olanzapine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00686998
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2013-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00686998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00686998, "Phase IIA Study in Patients With Schizophrenia". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00686998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*